Symbols / ADXN
ADXN Chart
About
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.93M |
| Enterprise Value | 842.99M | Income | -6.20M | Sales | 158.54K |
| Book/sh | 0.07 | Cash/sh | 0.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -145.00 | PEG | — |
| P/S | 56.34 | P/B | 110.08 | P/C | — |
| EV/EBITDA | -343.12 | EV/Sales | 5317.29 | Quick Ratio | 1.91 |
| Current Ratio | 2.01 | Debt/Eq | 0.61 | LT Debt/Eq | — |
| EPS (ttm) | -9.33 | EPS next Y | -0.05 | EPS Growth | — |
| Revenue Growth | -15.00% | Earnings | — | ROA | -15.90% |
| ROE | -72.84% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -14.04% | Profit Margin | 0.00% | Shs Outstand | 1.23M |
| Shs Float | 93.86M | Short Float | 0.41% | Short Ratio | 0.55 |
| Short Interest | — | 52W High | 12.05 | 52W Low | 6.51 |
| Beta | 1.94 | Avg Volume | 6.25K | Volume | 152.00 |
| Target Price | — | Recom | None | Prev Close | $7.25 |
| Price | $7.25 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$7.25
Latest analyst target
3. DCF / Fair value
$-8.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.25
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-31 | up | HC Wainwright & Co. | Neutral → Buy | $30 |
- (ADXN) Movement as an Input in Quant Signal Sets - Stock Traders Daily Wed, 18 Feb 2026 16
- ADXN Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 04
- Why Adobe Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga Fri, 12 Sep 2025 07
- Liquidity Mapping Around (ADXN) Price Events - Stock Traders Daily Sat, 07 Feb 2026 08
- Is ADXN a good ESG investment - Trend Reversal & AI Forecasted Entry/Exit Points - mfd.ru ue, 10 Feb 2026 13
- Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga Mon, 20 Oct 2025 07
- Why (ADXN) Price Action Is Critical for Tactical Trading - Stock Traders Daily ue, 27 Jan 2026 08
- Addex Therapeutics (ADXN) Stock Price, News & Analysis - MarketBeat Wed, 16 Sep 2020 02
- Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga Mon, 20 Oct 2025 07
- ADXN Stock Price and Chart — SIX:ADXN - TradingView ue, 25 Jul 2017 21
- How Much Of Addex Therapeutics Ltd (VTX:ADXN) Do Institutions Own? - Yahoo Finance Australia Mon, 03 Dec 2018 08
- Addex Therapeutics (NASDAQ:ADXN) Trading 2% Higher – Here’s Why - Defense World ue, 24 Feb 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.66M | -1.87M | -10.19M | -15.15M |
| TotalUnusualItems | 17.43K | -317.29K | -264.36K | 211.69K |
| TotalUnusualItemsExcludingGoodwill | 17.43K | -317.29K | -264.36K | 211.69K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.91M | -2.50M | -10.80M | -15.35M |
| ReconciledDepreciation | 260.12K | 305.95K | 323.14K | 347.61K |
| EBITDA | -4.65M | -2.19M | -10.45M | -14.94M |
| EBIT | -4.91M | -2.50M | -10.78M | -15.29M |
| NetInterestIncome | 5.62K | 60.10K | 1.30K | -57.69K |
| InterestExpense | 3.55K | 3.87K | 27.95K | 63.01K |
| InterestIncome | 9.16K | 63.96K | 29.25K | 5.32K |
| NormalizedIncome | -4.93M | -2.18M | -10.54M | -15.56M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.06M | -10.56M | -20.80M | -15.35M |
| TotalExpenses | 3.16M | 3.86M | 11.96M | 18.42M |
| RentExpenseSupplemental | 35.57K | 47.28K | 37.51K | |
| TotalOperatingIncomeAsReported | -2.76M | -2.24M | -10.54M | -15.51M |
| DilutedAverageShares | 1.40M | 1.23M | 685.30K | 284.33K |
| BasicAverageShares | 817.61K | 619.23K | 376.54K | 284.33K |
| DilutedEPS | 8.40 | -16.80 | -55.20 | -54.00 |
| BasicEPS | 8.40 | -16.80 | -55.20 | -54.00 |
| DilutedNIAvailtoComStockholders | 7.06M | -10.56M | -20.80M | -15.35M |
| NetIncomeCommonStockholders | 7.06M | -10.56M | -20.80M | -15.35M |
| NetIncome | 7.06M | -10.56M | -20.80M | -15.35M |
| NetIncomeIncludingNoncontrollingInterests | 7.06M | -10.56M | -20.80M | -15.35M |
| NetIncomeDiscontinuousOperations | 11.97M | -8.06M | -10.00M | |
| NetIncomeContinuousOperations | -4.91M | -2.50M | -10.80M | -15.35M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -4.91M | -2.50M | -10.80M | -15.35M |
| OtherIncomeExpense | -2.16M | -317.29K | -264.36K | 211.69K |
| EarningsFromEquityInterest | -2.18M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 17.43K | -317.29K | -264.36K | 211.69K |
| NetNonOperatingInterestIncomeExpense | 5.62K | 60.10K | 1.30K | -57.69K |
| InterestExpenseNonOperating | 3.55K | 3.87K | 27.95K | 63.01K |
| InterestIncomeNonOperating | 9.16K | 63.96K | 29.25K | 5.32K |
| OperatingIncome | -2.76M | -2.24M | -10.54M | -15.51M |
| OperatingExpense | 3.16M | 3.86M | 11.96M | 18.42M |
| OtherOperatingExpenses | 856.27K | 870.49K | 808.98K | 1.31M |
| DepreciationAmortizationDepletionIncomeStatement | 192.70K | 11.75K | 8.81K | 347.61K |
| DepreciationAndAmortizationInIncomeStatement | 192.70K | 11.75K | 8.81K | 347.61K |
| DepreciationIncomeStatement | 192.70K | 11.75K | 8.81K | 347.61K |
| ResearchAndDevelopment | 435.19K | 942.71K | 7.88M | 9.01M |
| SellingGeneralAndAdministration | 1.68M | 2.03M | 3.26M | 7.75M |
| GeneralAndAdministrativeExpense | 1.68M | 2.03M | 3.26M | 7.75M |
| OtherGandA | 1.21M | 1.16M | 1.42M | 1.38M |
| InsuranceAndClaims | 225.77K | 628.60K | 1.59M | 1.59M |
| RentAndLandingFees | 35.57K | 47.28K | 37.51K | |
| SalariesAndWages | 242.59K | 238.53K | 253.09K | 4.74M |
| TotalRevenue | 404.10K | 1.61M | 1.42M | 2.92M |
| OperatingRevenue | 404.10K | 1.61M | 1.42M | 2.92M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 86.01M | 89.12M | 38.21M | 11.37M |
| OrdinarySharesNumber | 98.34M | 95.24M | 77.13M | 37.90M |
| ShareIssued | 184.35M | 184.35M | 115.35M | 49.27M |
| TotalDebt | 41.99K | 344.34K | 373.13K | 482.01K |
| TangibleBookValue | 9.68M | 1.15M | 4.91M | 16.93M |
| InvestedCapital | 9.68M | 1.15M | 4.91M | 16.93M |
| WorkingCapital | 2.74M | 1.34M | 4.55M | 17.81M |
| NetTangibleAssets | 9.68M | 1.15M | 4.91M | 16.93M |
| CapitalLeaseObligations | 41.99K | 344.34K | 373.13K | 482.01K |
| CommonStockEquity | 9.68M | 1.15M | 4.91M | 16.93M |
| TotalCapitalization | 9.68M | 1.15M | 4.91M | 16.93M |
| TotalEquityGrossMinorityInterest | 9.68M | 1.15M | 4.91M | 16.93M |
| StockholdersEquity | 9.68M | 1.15M | 4.91M | 16.93M |
| OtherEquityInterest | 64.62M | 64.62M | 64.62M | |
| GainsLossesNotAffectingRetainedEarnings | 31.06M | 29.81M | 25.77M | 24.44M |
| OtherEquityAdjustments | 31.06M | 29.81M | 25.77M | 24.44M |
| TreasuryStock | 869.71K | 909.57K | 6.28M | 11.70M |
| RetainedEarnings | -353.36M | -360.42M | -349.86M | -329.06M |
| AdditionalPaidInCapital | 266.38M | 266.19M | 269.51M | 283.98M |
| CapitalStock | 1.84M | 1.84M | 1.15M | 49.27M |
| CommonStock | 1.84M | 1.84M | 1.15M | 49.27M |
| TotalLiabilitiesNetMinorityInterest | 1.00M | 3.50M | 3.37M | 5.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 198.94K | 603.14K | 87.03K | 1.48M |
| EmployeeBenefits | 164.25K | 443.52K | 0.00 | 1.28M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 164.25K | 443.52K | 0.00 | 1.28M |
| NonCurrentDeferredLiabilities | 0.00 | 89.23K | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 89.23K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 34.69K | 70.38K | 87.03K | 194.32K |
| LongTermCapitalLeaseObligation | 34.69K | 70.38K | 87.03K | 194.32K |
| CurrentLiabilities | 802.09K | 2.89M | 3.28M | 4.13M |
| CurrentDeferredLiabilities | 0.00 | 234.98K | 0.00 | 0.00 |
| CurrentDeferredRevenue | 0.00 | 234.98K | 0.00 | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 7.31K | 273.96K | 286.11K | 287.70K |
| CurrentCapitalLeaseObligation | 7.31K | 273.96K | 286.11K | 287.70K |
| PayablesAndAccruedExpenses | 794.79K | 2.38M | 3.00M | 3.85M |
| CurrentAccruedExpenses | 518.85K | 1.24M | 1.60M | 1.86M |
| Payables | 275.94K | 1.15M | 1.40M | 1.99M |
| OtherPayable | 120.88K | 203.29K | ||
| TotalTaxPayable | 22.65K | 164.61K | 120.88K | 203.29K |
| AccountsPayable | 253.29K | 984.38K | 1.28M | 1.79M |
| TotalAssets | 10.68M | 4.64M | 8.28M | 22.54M |
| TotalNonCurrentAssets | 7.14M | 407.28K | 453.09K | 600.01K |
| NonCurrentPrepaidAssets | 7.09K | 54.34K | 54.35K | 57.91K |
| InvestmentsAndAdvances | 7.09M | 0.00 | ||
| LongTermEquityInvestment | 7.09M | 0.00 | ||
| InvestmentsinAssociatesatCost | 7.09M | 0.00 | ||
| NetPPE | 42.71K | 352.94K | 398.73K | 542.10K |
| AccumulatedDepreciation | -153.71K | -4.32M | -4.02M | -3.77M |
| GrossPPE | 196.42K | 4.67M | 4.41M | 4.32M |
| Leases | 111.64K | 1.73M | 1.47M | 1.30M |
| OtherProperties | 84.78K | 2.94M | 2.94M | 3.01M |
| MachineryFurnitureEquipment | 0.00 | 7.56K | 7.56K | 7.56K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.54M | 4.23M | 7.83M | 21.94M |
| OtherCurrentAssets | 7.97K | |||
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 169.65K | 217.01K | 270.39K | 1.12M |
| Receivables | 15.51K | 151.27K | 598.32K | 324.42K |
| OtherReceivables | 40.91K | 181.44K | 159.64K | |
| AccountsReceivable | 15.51K | 110.36K | 416.88K | 164.78K |
| CashCashEquivalentsAndShortTermInvestments | 3.35M | 3.87M | 6.96M | 20.50M |
| OtherShortTermInvestments | 6.50K | 848.00 | 3.17K | 17.14K |
| CashAndCashEquivalents | 3.34M | 3.87M | 6.96M | 20.48M |
| CashFinancial | 3.34M | 3.87M | 6.96M | 20.48M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.37M | -8.00M | -16.44M | -14.74M |
| RepurchaseOfCapitalStock | -1.76K | -8.95K | -3.49K | -332.00 |
| RepaymentOfDebt | -73.69K | -281.79K | -288.08K | -309.62K |
| IssuanceOfCapitalStock | 240.90K | 2.35M | 1.68M | 13.96M |
| CapitalExpenditure | -1.27K | -6.84K | -581.00 | -31.55K |
| EndCashPosition | 3.34M | 3.87M | 6.96M | 20.48M |
| BeginningCashPosition | 3.87M | 6.96M | 20.48M | 18.70M |
| EffectOfExchangeRateChanges | 99.68K | -356.95K | -196.22K | 122.47K |
| ChangesInCash | -623.42K | -2.73M | -13.33M | 1.67M |
| FinancingCashFlow | 104.92K | 5.26M | 3.10M | 16.40M |
| CashFlowFromContinuingFinancingActivities | 104.92K | 5.26M | 3.10M | 16.40M |
| NetOtherFinancingCharges | -14.85K | -28.74K | -523.11K | -2.65M |
| InterestPaidCFF | -9.22K | -21.61K | -48.90K | -63.01K |
| ProceedsFromStockOptionExercised | -36.46K | 3.26M | 2.29M | 5.47M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 239.13K | 2.34M | 1.67M | 13.96M |
| CommonStockPayments | -1.76K | -8.95K | -3.49K | -332.00 |
| CommonStockIssuance | 240.90K | 2.35M | 1.68M | 13.96M |
| NetIssuancePaymentsOfDebt | -73.69K | -281.79K | -288.08K | -309.62K |
| NetLongTermDebtIssuance | -73.69K | -281.79K | -288.08K | -309.62K |
| LongTermDebtPayments | -73.69K | -281.79K | -288.08K | -309.62K |
| InvestingCashFlow | 4.65M | -6.84K | 2.97K | -30.31K |
| CashFlowFromContinuingInvestingActivities | 4.65M | -6.84K | 2.97K | -30.31K |
| NetOtherInvestingChanges | 5.12M | |||
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 3.55K | 1.24K |
| SaleOfInvestment | 0.00 | 0.00 | 3.55K | 1.24K |
| NetBusinessPurchaseAndSale | -473.27K | 0.00 | 0.00 | |
| PurchaseOfBusiness | -473.27K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -1.27K | -6.84K | -581.00 | -31.55K |
| PurchaseOfPPE | -1.27K | -6.84K | -581.00 | -31.55K |
| OperatingCashFlow | -5.37M | -7.99M | -16.44M | -14.71M |
| CashFlowFromContinuingOperatingActivities | -5.37M | -7.99M | -16.44M | -14.71M |
| ChangeInWorkingCapital | -1.23M | 213.76K | 157.68K | -761.57K |
| ChangeInOtherWorkingCapital | -38.40K | 324.21K | -820.15K | |
| ChangeInOtherCurrentAssets | -13.62K | 2.32K | 13.98K | 47.78K |
| ChangeInPayablesAndAccruedExpense | -1.15M | -613.21K | -427.39K | 883.84K |
| ChangeInPrepaidAssets | -164.28K | 53.39K | 844.98K | -616.99K |
| ChangeInReceivables | 134.01K | 447.05K | -273.89K | -256.05K |
| ChangesInAccountReceivables | 93.11K | 306.51K | -252.09K | -96.41K |
| OtherNonCashItems | 400.57K | 2.11M | 3.90M | 1.21M |
| StockBasedCompensation | 3.68M | 1.18M | ||
| DepreciationAmortizationDepletion | 260.12K | 305.95K | 323.14K | 347.61K |
| DepreciationAndAmortization | 260.12K | 305.95K | 323.14K | 347.61K |
| Depreciation | 260.12K | 305.95K | 323.14K | 347.61K |
| OperatingGainsLosses | -11.86M | -62.64K | -11.39K | -150.46K |
| PensionAndEmployeeBenefitExpense | -95.22K | -62.64K | -11.39K | -150.46K |
| EarningsLossesFromEquityInvestments | 2.18M | 0.00 | 0.00 | |
| GainLossOnSaleOfPPE | 0.00 | -127.00 | ||
| GainLossOnSaleOfBusiness | -13.94M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 7.06M | -10.56M | -20.80M | -15.35M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ADXN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|